% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mair:304124,
      author       = {M. J. Mair and J.-M. Werner and J. Weller and E. Barci and
                      S. Katzendobler and J. Isakaj and L. Berchtold and T. Aras
                      and R. Stürzl and J. Hennenberg and J. Reis and H. C. Puhr
                      and T. Schabhüttl and B. Kiesel and G. Widhalm and A.
                      Wöhrer and T. Nakuz and M. Hacker and J. Furtner and S.
                      Schönecker and P. Harter$^*$ and L. von Baumgarten$^*$ and
                      A. S. Berghoff and N. Thon and M. Preusser and N. L.
                      Albert$^*$},
      title        = {{P}rognostic stratification of newly diagnosed {IDH}-mutant
                      gliomas by [18{F}]fluoroethyltyrosine and [11{C}]methionine
                      {PET} - a retrospective, bicentric cohort study.},
      journal      = {Neuro-Oncology},
      volume       = {nn},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2025-01787},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Improved prognostic stratification including imaging-based
                      parameters is needed to guide treatment decisions in
                      IDH-mutant glioma.In this bicentric retrospective study, 457
                      patients with IDH-mutant glioma and [18F]fluoroethyltyrosine
                      or [11C]methionine positron emission tomography (PET) prior
                      to radiotherapy or systemic treatment were included.
                      Associations of maximum and mean tumor-to-background ratios
                      (TBRmax/TBRmean) and PET-positive volume (PET volume) with
                      time to next intervention (TTNI) and overall survival (OS)
                      were analyzed.Overall, 251 $(54.9\%)$ patients with
                      astrocytoma and 206 $(45.1\%)$ with oligodendroglioma were
                      included. In patients with astrocytoma who underwent PET
                      before resection, measurable disease according to PET RANO
                      1.0 criteria was associated with shorter TTNI compared to
                      no/non-measurable disease (median 46.0 vs. 67.9 months;
                      p=0.004). Univariable analysis showed an association of TTNI
                      with TBRmax, TBRmean and PET volume in astrocytoma and PET
                      volume in oligodendroglioma. Multivariable analyses
                      including age, WHO grade, extent of resection, postoperative
                      treatment and magnetic resonance imaging (MRI)-based tumor
                      extent indicated an association of TTNI with TBRmax (HR 1.48
                      $[95\%CI:$ 1.09-2.01]) and TBRmean (HR 1.93 $[95\%CI:$
                      1.14-3.27]) in astrocytoma and PET volume (HR [10 ml
                      increase]: 1.18 $[95\%CI:$ 1.03-1.36]) in oligodendroglioma.
                      In astrocytoma, also OS was related to TBRmax (HR: 1.40
                      $[95\%CI:$ 1.13-1.74]), TBRmean (HR: 1.97 $[95\%CI:$
                      1.21-3.22]), and PET volume (HR: 1.23 $[95\%CI:$ 1.10-1.37])
                      in univariable analysis. Further analyses considering
                      timepoint of PET showed consistent results.In this
                      retrospective study, amino acid PET parameters were
                      associated with outcome in newly diagnosed IDH-mutant
                      glioma. Future clinical trials should include PET imaging to
                      define imaging-based prognostic signatures.},
      keywords     = {astrocytoma (Other) / glioma (Other) / oligodendroglioma
                      (Other) / positron emission tomography (Other) / prognosis
                      (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40856188},
      doi          = {10.1093/neuonc/noaf196},
      url          = {https://inrepo02.dkfz.de/record/304124},
}